Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

Stefano Sestini; Mattia Boeri; Alfonso Marchiano; Giuseppe Pelosi; Carlotta Galeone; Carla Verri; Paola Suatoni; Nicola Sverzellati; Carlo La Vecchia; Gabriella Sozzi; Ugo Pastorino

doi:10.18632/oncotarget.27256

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening

PDF | How to cite

Oncotarget. 2019; 10:6043-6043. https://doi.org/10.18632/oncotarget.27256

Metrics: PDF 1139 views | ?

Stefano Sestini^1,*, Mattia Boeri^2,*, Alfonso Marchiano³, Giuseppe Pelosi^4,5, Carlotta Galeone⁶, Carla Verri², Paola Suatoni¹, Nicola Sverzellati⁷, Carlo La Vecchia^8,*, Gabriella Sozzi^2,*, Ugo Pastorino^1,*

¹ Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
² Unit of Tumor Genomics, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
³ Unit of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
⁴ Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
⁵ Department of Clinical and Biomedical Sciences Luigi Sacco, University of Milan, Milan, Italy
⁶ Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy
⁷ Department of Clinical Sciences, Section of Radiology, University of Parma, Milan, Italy
⁸ Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
^* These authors have contributed equally to this work

Published: October 15, 2019

This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows:

A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

Original article: Oncotarget. 2015; 6:32868–32877. DOI: https://doi.org/10.18632/oncotarget.5210.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27256

Publication Alerts

Corrections:

Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening